Immunization in patients with HIV infection: Are practical recommendations possible?

Drugs

Volumn 68, Issue 11, 2008, Pages 1473-1481

  Eley, Brian ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

Author keywords

Children; HIV infections; Immunisation programmes; Influenza vaccines, therapeutic use; Pneumococcal vaccine conjugate, therapeutic use; Rotavirus vaccines, therapeutic use

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; YELLOW FEVER VACCINE;

AFRICA; CHILDHOOD DISEASE; DEVELOPING COUNTRY; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPETENCE; INFECTION PREVENTION; INFLUENZA; NOTE; STREPTOCOCCUS INFECTION;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CHILD; HIV INFECTIONS; HUMANS; MASS IMMUNIZATION; PRACTICE GUIDELINES AS TOPIC; VIRAL VACCINES; VIRUS DISEASES;

ROTAVIRUS;

EID: 47349113252     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868110-00001     Document Type: Note

References (49)

1. WHO. WHO vaccine-preventable diseases: monitoring system, 2006 global summary [online]. Available from URL: http://www.who.int/vaccines-documents/ GlobalSummary/GlobalSummary.pdf [Accessed 2007 Nov 20]
2. Otten M, Kezaala R, Fall A, et al. Public-health impact of accelerated measles control in the WHO African region 2000-2003. Lancet 2005; 366: 832-9
3. WHO. Resurgence of wild poliovirus type 1 transmission and effect of importation into polio free countries, 2002-2005. Wkly Epidemiol Rec 2006; 81: 63-8
4. Levine OS, O'Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet 2006; 367: 1880-2
5. Cunliffe N, Nakagomi O. Introduction of rotavirus vaccines in developing countries: remaining challenges. Ann Trop Paediatr 2007; 27: 157-67
6. Committee on Infectious Diseases, American Academy of Pediatrics. Recommended childhood and adolescent immunization schedule: United States, 2006. Pediatr 2006; 117: 239-40
7. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007 -September 2008. Ann Intern Med 2007; 147: 725-9
8. UNAIDS. AIDS epidemic update, December 2007 [online]. Available from URL: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf [Accessed 2007 Dec 3]
9. WHO, UNAIDS, UNICEF. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007 [online]. Available from URL: http://data.unaids.org/pub/Report/2007/ 20070925_oms_progress_ report_en.pdf [Accessed 2007 Dec 3]
10. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005; 24: 410-6
11. De Milito A, Morch C, Sonnerberg AS, et al. Loss of memory (CD27) B lymphocytes in HIV infection. AIDS 2001; 15: 957-64
12. Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178: 8212-20
13. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull WHO 2003; 81: 61-70
14. Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or defining? Lancet Infect Dis 2006; 6: 150-61
15. WHO. Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Wkly Epidemiol Rec 2006; 81: 190-5
16. Setse RW, Cutts F, Monze M, et al. HIV-1 infection as a risk factor for incomplete childhood immunization in Zambia. J Trop Pediatr 2006; 52: 324-8
17. Fallo A, Torrado L, Sanches A, et al. Delayed complications of Bacille Calmette-Guerin (BCG) vaccination in HIV-infected children 2005. Proceedings of the 3rd International AIDS Society conference on HIV pathogenesis and treatment; 2005 Jul 24-27; Rio de Janeiro
18. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 14-8
19. WHO. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82: 193-6
20. WHO. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2004; 79: 130-42
21. Scott S, Moss WJ, Cousens S, et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007; 45: 1417-24
22. WHO. Yellow fever vaccine: WHO position paper. Wkly Epidemiol Rec 2003; 78: 349-59
23. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997; 16: 1177-9
24. Ryder RW, Oxtoby MJ, Mvula M, et al. Safety and immunogenicity of Bacille Calmette-Guérin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993; 122: 697-702
25. Melvin AJ, Mohan KM. Response to immunization with meassles, tetanus, and Haemophilus influenza type b vaccines in children who have human immunodeficiency virus type infection and are treated with highly active antiretroviral therapy. Pediatr 2003; 111: e641-4
26. Rosenblatt HM, Song LY, Nachman SA. Tetanus immunity after diphterhia, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005; 116: 698-703
27. Abzug MJ, Song L, Fenton T, et al. Pertussis booster vaccination in HIV-1-infected children receiving highly active antiretroviral therapy. Pediatr 2007; 120: e1190-202
28. Siriaksorn S, Puthanakit T, Sirisanthana T, et al. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006; 24: 3095-9
29. Lao-araya M, Puthanakit T, Aurpibul L, et al. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007; 25: 5324-9
30. Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatr 2006; 118: e315-22
31. Aurpibul L, Puthanakit T, Sirisanthana T, et al. Response to measles, mumps, rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 637-42
32. Tovo P, de Martino M, Gabiano C, et al. Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependant antigen administrations on HIV-1 progression. Italian register for HIV infection in children. Vaccine 2000; 18: 1203-9
33. Klugman KP, Madhi SA, Heubner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8
34. Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365: 1139-46
35. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-7
36. Abzug MJ, Pelton SI, Song L, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 920-9
37. Tangsinmankong N, Kamchaisatian W, Day NK, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 2004; 92: 558-64
38. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 1999; 355: 2106-11
39. Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18: 1210-3
40. WHO. Rotavirus vaccines. Wkly Epidemiol Rec 2007; 82: 285-95
41. Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet 2001; 358: 550-5
42. WHO. Influenza vaccines. Wkly Epidemiol Rec 2005; 80: 279-87
43. Zanetti AR, Amendola A, Besana S, et al. Safety and immunogenicicty of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20: B29-32
44. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006; 6: 138
45. Gallagher KM, Juhasz M, Harris NS, et al., for the Adult and adolescent spectrum of HIV disease group. Predictors of influenza vaccination in HIV-infected patients in the United States, 1990-2002. J Infect Dis 2007; 196: 339-46
46. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006; 333: 912-5
47. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139: 305-10
48. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 2006; 194: 247-55
49. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007; 25: 2975-82